The Global PEGylated Protein Therapeutics Market is poised to value over USD 22.3 billion by 2028 end at a CAGR of over 6.4% during the forecast period 2022 to 2028.
PEGylation is the process by which polyethylene glycol polymer chains are covalently and non-covalently attached to molecules such as a drug, therapeutic protein, or vesicle. The market for PEGylated protein therapeutics is expected to grow significantly during the forecast period, owing primarily to an increase in PEGylation demand, an increase in the number of chronic diseases, and the presence of strong pipeline drugs. Furthermore, PEGylated molecules provide benefits such as extended half-life, reduced toxicity, lower immunogenicity, and increased proteolytic protection, which support market growth. On the other hand, higher PEGylation process costs and the expiration of certain drug patents are expected to stifle market growth. The ongoing clinical trials being conducted by many pharmaceutical companies, as well as the high demand for disease-specific novel treatments, are expected to accelerate the overall growth of the PEGylated protein therapeutics market during the forecast period. Furthermore, an increase in special designation from regulatory authorities is expected to boost the market’s overall growth. However, many pharmaceutical companies’ limited operating revenue opportunities for research and development of targeted therapies, as well as low healthcare budgets in some developing countries, are expected to stymie the growth of the PEGylated protein therapeutics market in the coming years. With over 10 PEGylated drugs approved by the US FDA and 20 drugs in clinical trials, PEGylated protein therapeutics is expected to be a highly lucrative market in terms of revenue. PEGylated drugs of the first generation were obtained through random PEGylation. Adagen and Oncaspar are two examples. The majority of drugs in clinical trials are PEGylated with larger PEGs than first generation therapeutics in order to increase half-life and decrease frequency of administration. In phase III clinical trials, Bayer, Novo Nordisk, and Baxalta have four long-acting haemophilia drugs based on PEGylated recombinant coagulation factors. During the forecast period, these promising ongoing clinical trials are expected to provide significant market opportunities.
The astute research report on PEGylated Protein Therapeutics market provides intricate details for analyzing appropriate parameters and valuable insights. The report offers extensive information about this business to help bring forth the growth potential of the market across various segments and provides the clients with a comprehensive analysis of factors like market size, market growth trends, competitive landscape, product utilization, regional growth prospects, and application potential, etc. The data provided in the report has been gathered from a wide variety of sources by using primary and secondary research. This PEGylated Protein Therapeutics research report also provides crucial insights into consumer behaviour, brand positioning, pricing analysis, and key player strategies. The market overview included in the PEGylated Protein Therapeutics research report incorporates critical factors procured from industry analysts, prominent players as well as trade and industrial organizations.
The report on PEGylated Protein Therapeutics market offers up-to-date information on the factors impeding the market growth which shall provide vendors with crucial insights into understanding the market dynamics thereby aiding the clients to sketch out a better business strategy. These factors will help them identify market growth opportunities. Furthermore, FutureWise research analysts provide timely assistance to their customers in understanding eccentric market parameters more effectively thereby leading to better decision-making.
Get a Sample of the PEGylated Protein Therapeutics Market Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=10427&page=requestsample
The PEGylated Protein Therapeutics market research report is segmented – by product type, by application type, by sales channel, and by region. It also consists of insights regarding the revenue value and sales volume during the forecasted timeframe of 2022 to 2028.
PEGylated Protein Therapeutics Market Segmentation:
By Product Type
Colony Stimulating Factor
Interferon
Erythropoietin (EPO)
Recombinant Factor VIII
Monoclonal Antibody
Enzyme
Others
By Application Type
Cancer
Autoimmune Disease
Hepatitis
Multiple Sclerosis
Hemophilia
Gastrointestinal Disorder
Others
By Sales Channel
Hospital Pharmacy
Online Provider
Retail Pharmacy
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
PEGylated Protein Therapeutics Market Regional Analysis:
The report provides a complete evaluation of the potential amplification of the PEGylated Protein Therapeutics Market in pivotal geographic regions such as North America, Asia Pacific, Europe, Latin America and Middle East & Africa.
Competitive Landscape:
Some of the key market players are
Amgen Inc.
AstraZeneca PLC
Biogen, Inc.
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,),
Horizon Pharma plc.
Leadiant Biosciences S.p.A.
Merck & Co., Inc. (Schering-Plough Corporation)
Pfizer Inc.
Shire plc (Baxalta)
UCB S.A.
Enzon Pharmaceuticals, Inc
Takeda Pharmaceutical Company Limited
Affymax, Inc
Novo Nordisk A/S
Teva Pharmaceutical Industries Ltd
Nektar
Leadiant Biosciences, Inc
Eiger BioPharmaceuticals
Halozyme, Inc
Biocad
PharmaEssentia Corporation
FutureWise Key Takeaways:
Growth prospects
SWOT analysis
Key market trends
Key data-points affecting market growth
Objectives of the Study:
To provide an extensive analysis of the global PEGylated Protein Therapeutics market by product type, by application type, by sales channel, and by region
To carter complex data and information on the characteristics influencing the market growth (drivers, restraints, opportunities, and industry-specific restraints)
To predict and assess micro-markets and the overall market
To anticipate the market size, in key geographical regions (along with countries)— North America, Europe, Asia Pacific, Latin America and the Middle East and Africa
To estimate and inspect competitive landscape mapping- technological advancements, product launches, mergers and expansions
Flexible Delivery Model:
Our delivery model is flexible, so you can suggest changes to the content/scope as per your requirement
With purchase of any license of the report the customization Mobility Care offered is free of charge
You can directly forward your requirements/changes to the current table of content to: [email protected]
About FutureWise Market Research:
We specialize in high-growth niche market research, offering flexibility, agility, and customized solutions for our clients. By providing our clients with market insights and consulting services, we ensure they stay on top of their industries for years to come.
FutureWise Market Research
Vinay T – Head of Business Development
Email: [email protected]
UK: +44 141 628 9353 | USA: +1 347 709 4931
Website: www.futurewiseresearch.com
